VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability and safety.
"EVP-6124 appears to be safe and was well tolerated over a month of dosing," commented Kees Been, CEO of EnVivo. "Most excitingly, the cognition improvement was observed on top of the effect of acetylcholinesterase inhibitors the patients were already taking. This is a strong indicator of a biologic and potentially useful clinical effect."
Minimal treatment-emergent adverse effects were observed during the trial and there were no serious adverse events. Improvement in a number of cognition measures in EVP-6124 treated patients were observed compared to placebo treated patients. These included measures of attention, verbal and language fluency, and executive function. Four of the eight cognition measures showed statistically significant dose-dependent effects and two others showed a trend towards improvement.
About EnVivo Pharmaceuticals
EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase I studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharma.com.
EnVivo Pharmaceuticals
